Animal models of tyrosinemia

Journal of Nutrition

Volumn 137, Issue 6, 2007, Pages

  Nakamura, Kimitoshi ^a   Tanaka, Yasuhiko ^a   Mitsubuchi, Hiroshi ^a   Endo, Fumio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; CASPASE INHIBITOR; CYTOCHROME C; ETHYLNITROSOUREA; FAH PROTEIN; HOMOGENTISIC ACID; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG;

ALBINISM; APOPTOSIS; CELL FUSION; CLINICAL FEATURE; COMPREHENSION; CONFERENCE PAPER; EPITHELIUM CELL; FANCONI RENOTUBULAR SYNDROME; GENE; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; HEMATOPOIETIC STEM CELL; KIDNEY TUBULE CELL; KIDNEY TUBULE EPITHELIUM; LIVER; LIVER CELL; LIVER FAILURE; LIVER INJURY; LIVER MITOCHONDRION; LIVER REGENERATION; MICROARRAY ANALYSIS; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PERINATAL PERIOD; PHENOTYPE; PROTEIN SECRETION; SCIENCE; TYROSINEMIA; VISCERA;

ANIMALIA; MUS;

EID: 34249816807     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/137.6.1556s     Document Type: Conference Paper

References (28)

1. Berger R, Smit GP, Stoker-de Varies SA, Duran M, Ketting D, Wadman SK. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Clin Chim Acta. 1981;114:37-44.
2. Kvittingen EA, Jellum E, Stokke O. Assay of fumarylacetoacetate fumarylhydrolase in human liver: deficient activity in a case of hereditary tyrosinemia. Clin Chim Acta. 1981;115:311-9.
3. Mitchell GA, Lambert M, Tanguay RM. Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic andmolecular bases of inherited disease. 7th ed. New York: McGraw-Hill. 1995. p. 1077-106.
4. Sakai K, Kitagawa T. An atypical case of tyrosinosis. Part 1. Jikei Med J. 1957;2:1-10.
5. Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, Gauthier M, Lacroix J, Vanasse M, et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med. 1990;322:432-7.
6. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA. 1977;74:4641-5.
7. Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet. 1992;340:813-7.
8. Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM. Type 1 hereditary tyrosinemia: evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest. 1992;90:1185-92.
9. Awata H, Endo F, Tanoue A, Kitano A, Nakano Y, Matsuda I. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I. Biochim. Biophys. Acta. 1994;1226:168-72.
10. Gluecksohn-Waelsch S. Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse. Cell. 1979;16:225-37.
11. Ruppert S, Kelsey G, Schedl A, Schmid E, Thies E, Schutz G. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev. 1992;6: 1430-43.
12. Klebig ML, Russell LB, Rinchik EM. Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus. Proc Natl Acad Sci USA. 1992;89:1363-7.
13. Ruppert S, Bothart M, Bosch F, Schmid W, Fournier REK, Schutz G. Two genetically defined trans-acting loci coordinately regulate over-lapping sets of liver-specific genes. Cell. 1990;61:895-904.
14. Kelsey G, Ruppert S, Beermann F, Grund C, Tanguay RM, Schutz G. Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type I. Genes Dev. 1993;7:2285-97.
15. Grompe M, Al-Dhalimy M, Finegold M, Ou CN, Burlingame T, Kennaway NG, Soriano P. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev. 1993;7:2298-307.
16. Trigg MJ, Gluecksohn-Waelsch S. Ultrastructural basis of biochemical effects in a series of lethal alleles in the mouse. J Cell Biol. 1973;58:549-63.
17. Grompe M, Lindstedt S, Al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, Ou CA, Finegold M. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinemia type I. Nat Genet. 1995;10:453-60.
18. Endo F, Kubo S, Awata H, Kiwaki K, Katoh H, Kanegae Y, Saito I, Miyazaki J, Yamamoto T, et al. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem. 1997;272:24426-32.
19. Endo F, Katoh H, Yamamoto S, Matsuda I. A murine model for type III tyrosinemia: lack of immunologically detectable 4-hydroxyphenylpyruvic acid dioxygenase enzyme protein in a novel mouse strain with hypertyrosinemia. Am J Hum Genet. 1991;48:704-9.
20. Endo F, Awata H, Katoh H, Matsuda I. A nonsense mutation in the 4-hydroxyphenylpyruvic acid dioxygenase gene (Hpd) causes skipping of the constitutive exon and hypertyrosinemia in mouse strain III. Genomics. 1995;25:164-9.
21. Kubo S, Kiwaki K, Awata H, Katoh H, Kanegae Y, Saito I, Yamamoto T, Miyazaki J, Matsuda I, et al. In vivo correction with recombinant adenovirus of 4-hydroxyphenylpyruvic aciddioxygenase deficiencies in strain III mice. Hum Gene Ther. 1997;8:65-71.
22. Kubo S, Sun MS, Miyahara M, Umeyama K, Urakami K, Yamamoto T, Jakobs C, Matsuda I, Endo F. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors. Proc Natl Acad Sci USA. 1998;95:9552-7.
23. Sun MS, Hattori S, Kubo S, Awata H, Matsuda I, Endo F. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice. J Am Soc Nephrol. 2000;11:291-300.
24. Shackel NA, Gorrell MD, McCaughan GW. Gene array analysis and the liver. Hepatology. 2002;36:1313-25.
25. Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P, Partridge NC. Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics. J Biol Chem. 2003;278:19723-31.
26. Tanaka Y, Nakamura K, Matsumoto S, Kimoto Y, Tanoue A, Tsujimoto G, Endo F. Gene expression profiles of homogentisate-treated Fah-/-Hpd-/-mice using DNA microarrays. Mol Genet Metab. 2006;89:203-9.
27. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, Wang X, Finegold M, Weissman IL, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229-34.
28. Wang X, Willenbring H, Akkari Y, Torimaru Y, Foster M, Al-Dhalimy M, Lagasse E, Finegold M, Olson S, et al. Cell fusion is the principal source of bone-marrow-derived hepatocytes. Nature. 2003;422:897-901.